107 related articles for article (PubMed ID: 29382252)
1. Synthetic siRNA targeting human papillomavirus 16 E6: a perspective on in vitro nanotherapeutic approaches.
Togtema M; Jackson R; Grochowski J; Villa PL; Mellerup M; Chattopadhyaya J; Zehbe I
Nanomedicine (Lond); 2018 Feb; 13(4):455-474. PubMed ID: 29382252
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of cervical cancer cell growth in vitro and in vivo by lentiviral-vector mediated shRNA targeting the common promoter of HPV16 E6 and E7 oncogenes.
Zhou J; Li B; Peng C; Wang F; Fu Z; Zhou C; Hong D; Ye F; Lü W; Xie X
Antiviral Res; 2013 May; 98(2):305-13. PubMed ID: 23523766
[TBL] [Abstract][Full Text] [Related]
3. The PEI-introduced CS shell/PMMA core nanoparticle for silencing the expression of E6/E7 oncogenes in human cervical cells.
Saengkrit N; Sanitrum P; Woramongkolchai N; Saesoo S; Pimpha N; Chaleawlert-Umpon S; Tencomnao T; Puttipipatkhachorn S
Carbohydr Polym; 2012 Oct; 90(3):1323-9. PubMed ID: 22939347
[TBL] [Abstract][Full Text] [Related]
4. Eradication of cervical cancer in vivo by an AAV vector that encodes shRNA targeting human papillomavirus type 16 E6/E7.
Sato N; Saga Y; Uchibori R; Tsukahara T; Urabe M; Kume A; Fujiwara H; Suzuki M; Ozawa K; Mizukami H
Int J Oncol; 2018 Mar; 52(3):687-696. PubMed ID: 29344635
[TBL] [Abstract][Full Text] [Related]
5. Systemic delivery of siRNA by actively targeted polyion complex micelles for silencing the E6 and E7 human papillomavirus oncogenes.
Nishida H; Matsumoto Y; Kawana K; Christie RJ; Naito M; Kim BS; Toh K; Min HS; Yi Y; Matsumoto Y; Kim HJ; Miyata K; Taguchi A; Tomio K; Yamashita A; Inoue T; Nakamura H; Fujimoto A; Sato M; Yoshida M; Adachi K; Arimoto T; Wada-Hiraike O; Oda K; Nagamatsu T; Nishiyama N; Kataoka K; Osuga Y; Fujii T
J Control Release; 2016 Jun; 231():29-37. PubMed ID: 26979870
[TBL] [Abstract][Full Text] [Related]
6. Human Papillomavirus E6/E7-Specific siRNA Potentiates the Effect of Radiotherapy for Cervical Cancer in Vitro and in Vivo.
Jung HS; Rajasekaran N; Song SY; Kim YD; Hong S; Choi HJ; Kim YS; Choi JS; Choi YL; Shin YK
Int J Mol Sci; 2015 May; 16(6):12243-60. PubMed ID: 26035754
[TBL] [Abstract][Full Text] [Related]
7. Intratumor injection of small interfering RNA-targeting human papillomavirus 18 E6 and E7 successfully inhibits the growth of cervical cancer.
Fujii T; Saito M; Iwasaki E; Ochiya T; Takei Y; Hayashi S; Ono A; Hirao N; Nakamura M; Kubushiro K; Tsukazaki K; Aoki D
Int J Oncol; 2006 Sep; 29(3):541-8. PubMed ID: 16865269
[TBL] [Abstract][Full Text] [Related]
8. siRNA-induced immunostimulation through TLR7 promotes antitumoral activity against HPV-driven tumors in vivo.
Khairuddin N; Gantier MP; Blake SJ; Wu SY; Behlke MA; Williams BR; McMillan NA
Immunol Cell Biol; 2012 Feb; 90(2):187-96. PubMed ID: 21423261
[TBL] [Abstract][Full Text] [Related]
9. Promoting Vaginal Distribution of E7 and MCL-1 siRNA-Silencing Nanoparticles for Cervical Cancer Treatment.
Lechanteur A; Furst T; Evrard B; Delvenne P; Piel G; Hubert P
Mol Pharm; 2017 May; 14(5):1706-1717. PubMed ID: 28350964
[TBL] [Abstract][Full Text] [Related]
10. Gene silencing with siRNA targeting E6/E7 as a therapeutic intervention in a mouse model of cervical cancer.
Jonson AL; Rogers LM; Ramakrishnan S; Downs LS
Gynecol Oncol; 2008 Nov; 111(2):356-64. PubMed ID: 18755502
[TBL] [Abstract][Full Text] [Related]
11. Silencing of HPV 18 oncoproteins With RNA interference causes growth inhibition of cervical cancer cells.
Lea JS; Sunaga N; Sato M; Kalahasti G; Miller DS; Minna JD; Muller CY
Reprod Sci; 2007 Jan; 14(1):20-8. PubMed ID: 17636212
[TBL] [Abstract][Full Text] [Related]
12. HPV-16 E6/E7 promotes cell migration and invasion in cervical cancer via regulating cadherin switch in vitro and in vivo.
Hu D; Zhou J; Wang F; Shi H; Li Y; Li B
Arch Gynecol Obstet; 2015 Dec; 292(6):1345-54. PubMed ID: 26093522
[TBL] [Abstract][Full Text] [Related]
13. Selective silencing of viral gene expression in HPV-positive human cervical carcinoma cells treated with siRNA, a primer of RNA interference.
Jiang M; Milner J
Oncogene; 2002 Sep; 21(39):6041-8. PubMed ID: 12203116
[TBL] [Abstract][Full Text] [Related]
14. Activation of p53 in cervical cancer cells by human papillomavirus E6 RNA interference is transient, but can be sustained by inhibiting endogenous nuclear export-dependent p53 antagonists.
Koivusalo R; Mialon A; Pitkänen H; Westermarck J; Hietanen S
Cancer Res; 2006 Dec; 66(24):11817-24. PubMed ID: 17178878
[TBL] [Abstract][Full Text] [Related]
15. The synergistic therapeutic effect of cisplatin with Human papillomavirus E6/E7 short interfering RNA on cervical cancer cell lines in vitro and in vivo.
Jung HS; Erkin OC; Kwon MJ; Kim SH; Jung JI; Oh YK; Her SW; Ju W; Choi YL; Song SY; Kim JK; Kim YD; Shim GY; Shin YK
Int J Cancer; 2012 Apr; 130(8):1925-36. PubMed ID: 21630254
[TBL] [Abstract][Full Text] [Related]
16. New highly potent and specific E6 and E7 siRNAs for treatment of HPV16 positive cervical cancer.
Yamato K; Yamada T; Kizaki M; Ui-Tei K; Natori Y; Fujino M; Nishihara T; Ikeda Y; Nasu Y; Saigo K; Yoshinouchi M
Cancer Gene Ther; 2008 Mar; 15(3):140-53. PubMed ID: 18157144
[TBL] [Abstract][Full Text] [Related]
17. Induction of cell death in human papillomavirus 18-positive cervical cancer cells by E6 siRNA.
Yamato K; Fen J; Kobuchi H; Nasu Y; Yamada T; Nishihara T; Ikeda Y; Kizaki M; Yoshinouchi M
Cancer Gene Ther; 2006 Mar; 13(3):234-41. PubMed ID: 16138119
[TBL] [Abstract][Full Text] [Related]
18. In vitro and in vivo growth suppression of human papillomavirus 16-positive cervical cancer cells by E6 siRNA.
Yoshinouchi M; Yamada T; Kizaki M; Fen J; Koseki T; Ikeda Y; Nishihara T; Yamato K
Mol Ther; 2003 Nov; 8(5):762-8. PubMed ID: 14599809
[TBL] [Abstract][Full Text] [Related]
19. Microarray analysis identifies differentially expressed genes induced by human papillomavirus type 18 E6 silencing RNA.
Min W; Wen-li M; Zhao-hui S; Ling L; Bao Z; Wen-ling Z
Int J Gynecol Cancer; 2009 May; 19(4):547-63. PubMed ID: 19509549
[TBL] [Abstract][Full Text] [Related]
20. Human Papillomavirus 16 Oncoprotein Expression Is Controlled by the Cellular Splicing Factor SRSF2 (SC35).
McFarlane M; MacDonald AI; Stevenson A; Graham SV
J Virol; 2015 May; 89(10):5276-87. PubMed ID: 25717103
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
